EP0218678A1 - Verfahren zur behandlung von obstruktiven erkrankungen der atmungswege - Google Patents
Verfahren zur behandlung von obstruktiven erkrankungen der atmungswegeInfo
- Publication number
- EP0218678A1 EP0218678A1 EP19860902624 EP86902624A EP0218678A1 EP 0218678 A1 EP0218678 A1 EP 0218678A1 EP 19860902624 EP19860902624 EP 19860902624 EP 86902624 A EP86902624 A EP 86902624A EP 0218678 A1 EP0218678 A1 EP 0218678A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- pyrido
- dihydro
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Definitions
- 11-substituted 5,ll-dihydro-6H-pyrido[2,3-b] [1,4] benzodiazepin-6-ones such as 11-aminoacetyl- 5,ll-dihydro-6H-pyrido[2,3-6] [1,4] benzodiazepin-6- ones or the non-toxic pharmacologically acceptable salts thereof, are tricyclic compounds having the structural formula
- R.. is hydrogen or alkyl of 1 to 4 carbon atoms
- R 2 is hydrogen chlorine or methyl
- R_ and R . are each alkyl of 1 to 5 carbon atoms or, together with each other and the nitrogen atom to which they are attached, camphidino, pyrrolidino, morpholino, piperidino, methyl-piperidino, ethyl-piperidino, piperazino, N 1 -methyl-piperazino, N'-ethyl- piperazino, N'-hydroxyethyl-piperazino, N'-benzyl- piperazino, N'-methylbenzyl-piperazino or hexamethyle- neimino.
- Pirenzepine is an antimuscarinic agent which has been demonstrated to be an effective inhibitor of gastric secretion and is currently available in Europe as an anti-ulcer medication. It is thought to specifically antagonize a subtype of muscarinic receptors; it inhibits gastric secretion but not other muscarinic activities (i.e., gastric emptying, esophageal motility) and neither mydriasis nor tachy ⁇ cardia occur with its administration. It has been reported to be relatively ineffective (compared to atropine) in smooth muscle preparations from the intestine and vasculature. Grass, and Skorodin (Am. Rev. Respir. Dis.
- piren ⁇ zepine to inhibit vagally-induced bronchoconstric ⁇ tion in mammals.
- the compounds of the present invention, and specifically pirenzepine have the advantage of atropine of being able to be adminis ⁇ tered orally without concurrent side effects due to selectivity for a receptor subtype which appears to be limited to the vagal bronchoconstructive pathway (and the vagal secretary pathway in the stomach) .
- compounds of the present invention are better choices of antimuscarinic agents for airways obstruc ⁇ tive disease because they are potent inhibitors of vagally - induced bronchoconstriction and can be given orally without crossing the blood brain barrier or causing other side effects.
- Pulmonary resistance was calculated from raw data signals of transpulmonary pressure, volume, and flow using a Z80 CPU computer.
- a saline filled polyethylene catheter was placed in the thoracic aorta, threaded via the femoral artery in order to measure phasic aortic pressure and heart rate.
- the animals were paralyzed with succinyl- choline and mechanically ventilated.
- the cervical vagus nerve was isolated bilaterally and transected.
- the distal cut ends of the cervical vagi were electrically stimulated simultaneously for 1 minute duration (40 Hz frequency, 0.3 msec pulse duration, 10 volts intensity) , and the maximum increase in pulmonary resistance and decrease in heart rate determined. Two stimulations were performed 3 minutes apart. Intravenous infusions of antagonist drug, either atropine or pirenzepine, were given in 5 increasing concentrations and vagal stimulation repeated. Stimulations were performed at 6 and 9 minutes after each drug infusion was begun. Six animals received atropine and 6 animals pirenzepine. For each dose of antagonist drug, the percent inhibi ⁇ tion of the change in pulmonary resistance or heart rate induced by vagal stimulation was determined and an inhibition curve constructed. The dose of drug required to antagonize by 50% the effect of vagal stimulation on pulmonary resistance and heart rate (IC 50) was calculated from the curves. The results appear in the following table:
- pirenzepine shows a differential inhibitory activity, with a 42-fold greater inhibitory activity on bronchoconstriction as compared to the decrease in heart rate.
- Ml pirenzepine sensitive
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72508085A | 1985-04-19 | 1985-04-19 | |
| US725080 | 1985-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0218678A1 true EP0218678A1 (de) | 1987-04-22 |
Family
ID=24913083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19860902624 Pending EP0218678A1 (de) | 1985-04-19 | 1986-03-31 | Verfahren zur behandlung von obstruktiven erkrankungen der atmungswege |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP0218678A1 (de) |
| WO (1) | WO1986006278A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0330756B1 (de) * | 1987-12-22 | 1996-03-27 | Byk Gulden Lomberg Chemische Fabrik GmbH | Thienotricyclen zur Behandlung von Erkrankungen der Bronchien |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1795183B1 (de) * | 1968-08-20 | 1972-07-20 | Thomae Gmbh Dr K | 5,11-Dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-on-derivate und Arzneimittel |
-
1986
- 1986-03-31 WO PCT/US1986/000644 patent/WO1986006278A1/en not_active Application Discontinuation
- 1986-03-31 EP EP19860902624 patent/EP0218678A1/de active Pending
Non-Patent Citations (1)
| Title |
|---|
| See references of WO8606278A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1986006278A1 (en) | 1986-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100435611B1 (ko) | 에피나스틴을포함하는동통치료용약제학적조성물 | |
| US4753789A (en) | Method for treating nausea and vomiting | |
| US20030018043A1 (en) | Compositions and methods for treating opiate intolerance | |
| US5922749A (en) | Medicaments for treating nausea and vomiting | |
| JP2007505139A (ja) | 診断された呼吸疾患を有する患者もしくは診断未確定の呼吸疾患を有する患者におけるオピオイド鎮痛薬の投与に関連する危険性を減少するための方法および組成 | |
| US4117161A (en) | Method of pharmacologically treating drug addiction with alpha-methyl-para-tyrosine | |
| RU2126254C1 (ru) | Применение бисфенилалкилпиперазинов для лечения расстройств, вызванных злоупотреблением веществами, и способ лечения | |
| JP2001513814A (ja) | 小児科手術におけるレボブピバカインの使用 | |
| US4877794A (en) | 2-Alkoxy-n-(1-azabicyclo(2.2.2)oct-3-yl) benzamide and thiobenzamide compositions and the use thereof to treat schizophrenia | |
| RU2413512C1 (ru) | Средство, обладающее каппа-опиоидной агонистической активностью | |
| EP0218678A1 (de) | Verfahren zur behandlung von obstruktiven erkrankungen der atmungswege | |
| US5240954A (en) | Medicaments | |
| US4380550A (en) | Guanfacine in treating opiate addiction | |
| EP0694299A1 (de) | Verwendung vom einem Bicycloheptan-Derivat | |
| JPH02209808A (ja) | 物質嗜癖の治療法 | |
| RU2229297C2 (ru) | Терапевтический агент для лечения стеноза позвоночного канала | |
| JPH0517358A (ja) | 睡眠誘起性無呼吸症治療剤 | |
| EP0418327B1 (de) | Eregolin abkoemmlinge mit anti-emesis wirkung | |
| Swann et al. | The alkalinisation of bupivacaine for intercostal nerve blockade | |
| Chung et al. | New Drugs: Respiratory and allergic disease—I | |
| US5026699A (en) | Use of 5,11-dihydro-6H-pyrido[2,3-b][1,4]-benzodiazepin-6-ones substituted in the 11-position for treating bradycardia and bradyarrhythmia in human and veterinary medicine | |
| US3483294A (en) | 1,1-diethyl-2-methyl - 3 - diphenylmethylenepyrrolidinium halide compositions and therapy | |
| Moses einhorn | The use of a new antispasmodic drug in gastro-enterology a preliminary report | |
| Chaudhari et al. | Analgesic 4 drugs | |
| JP5142991B2 (ja) | １−（３−クロロフェニル）−３−アルキルピペラジンを含む食欲障害治療用医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: YAMAMURA, HENRY, I. Inventor name: HALONEN, MARILYN Inventor name: BLOOM, JOHN, W. Inventor name: LAWRENCE, LOWELL, J. |